ERBB2 and breast cancer: Among HER2‐positive (HER2+) breast cancers, patients with PI3K mutations account for a considerable proportion; thus, the accurate annotations of PI3K mutation in the disease progression will be critical for genomics‐guided diagnosis and treatment.